[177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial

Conclusion: Long-term outcomes with [177Lu]Lu-PSMA-617 administered earlier in the prechemotherapy setting are comparable to those with docetaxel.

Source: Journal of Nuclear Medicine - November 2, 2023 Category: Nuclear Medicine Authors: Satapathy, S., Mittal, B. R., Sood, A., Das, C. K., Mavuduru, R. S., Goyal, S., Shukla, J., Singh, S. K. Tags: Brief Communications Source Type: research